Copyright 2006 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2006
Objective: It has recently been reported that epidermal growth factor receptor tyrosine kinase inhibition might be a more effective treatment strategy in patients harboring specific EGFR mutations. These mutations are prevalent in 3% to 7% of non–small-cell lung carcinomas. Our objective was to examine whether these mutations might be more common at other upper aerodigestive cancer sites.
Design: We extracted DNA from 20 head and neck squamous cell tumors and 4 squamous cell carcinoma cell lines and sequenced the receptors using previously published primer pairs. We then compared the results against reported mutations.
Carlson ML, Wuertz BR, Lin J, Adams GL, Taylor RS, Ondrey FG. P226 Lack of Exon 19 and 21 EGFR Mutations in Squamous Cell Head and Neck Cancer Specimens and Cell Lines. Arch Otolaryngol Head Neck Surg. 2006;132(8):910. doi:10.1001/archotol.132.8.910-a